Management of hypercholesterolaemia in postmenopausal women

Drugs and Aging

Volumn 19, Issue 3, 2002, Pages 169-178

  Davidson, Michael H ^a   Maki, Kevin C ^a   Karp, Sherry Katz ^a   Ingram, Kate A ^a  

^a RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CHOLECYSTITIS; CHOLELITHIASIS; DIET; DYSLIPIDEMIA; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID BLOOD LEVEL; LIVER TOXICITY; MYALGIA; MYOPATHY; OBESITY; OVARIECTOMY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; THROMBOSIS;

EID: 0036279821     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219030-00002     Document Type: Review

References (88)

1. Sex differences, hormones, and heart disease
2. Postmenopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins
3. Menopause and heart disease. A review
4. Sex differences in coronary heart disease: Why are women so superior? The 1995 Ancel Keys Lecture
5. Changes in LDL density across the menopausal transition
6. How do we explain the clinical benefits of estrogen? From bedside to bench
7. Influence of age and menopause on serum lipids and lipoproteins in healthy women
8. Dense low density lipoproteins and coronary artery disease
9. Summary of the Second Report of the National Cholesterol Panel (NCEP) on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
10. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults
11. Prevalence of high blood cholesterol among US adults: An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
13. The lipid treatment assessment project (L-TAP): A multi-center survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
14. Inadequate treatment with 3-hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors by health care providers
15. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
16. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and 'normal' cholesterol levels
17. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
18. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
19. Adherence to national cholesterol education program treatment goals in postmenopausal women with heart disease
20. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada
21. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
22. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
23. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) trial
24. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
25. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
26. Effect of niacin on atherosclerotic cardiovascular disease
27. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease
28. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki heart study
29. Helsinki heart study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
30. Guide to preventive cardiology for women
31. Systematic review on the risk and benefit of different cholesterol-lowering interventions
32. Long term maintenance of a low-fat diet: Durability of fat-related maintenance habits in the Women's Health Trial
33. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: Importance of diet, exercise, weight control, and drug therapy
34. Oat products and lipid lowering: A meta-analysis
35. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: Meta-analysis of 8 controlled trials
36. The hypercholesterolemic effects of β-glucan in oatmeal and oat bran
37. A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: A controlled, double-blind, crossover study
38. Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia
39. Fiber: Forms and functions
40. Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose
41. High-molecular weight hydroxypropylmethylcellulose taken with or between meals is hypocholesterolemic in adult men
42. Lipid responses to plant sterol-enriched reduced-fat spreads incorporated into a NCEP Step 1 diet
43. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy
44. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population
45. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
46. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
47. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
48. Raloxifene lowers serum lipoprotein(a) in healthy postmenopausal women: A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens
49. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women
50. Oral versus transdermal hormone replacement therapy
51. Hormone replacement therapy and increased plasma concentration of C-reactive protein
52. Effectiveness of atorvastatin for decreasing low density lipoprotein cholesterol to NCEP treatment goals
53. The MRC/BHF Heart Protection Study: Preliminary results
54. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): Efficacy and tolerability of long-term treatment with lovastatin in women
55. Cardiovascular risk factors: Evaluation and treatment goals
56. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
57. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with Rosuvastatin versus Atorvastatin in patients with type IIa or IIb hypercholesterolemia
58. Use of nicotinic acid, bile acid-binding resins, and fibrates
59. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol
60. Clofibrate and niacin in coronary heart disease
61. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing
62. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease
63. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia
64. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters in patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state
65. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or Iib hyperlipidemia
66. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
67. Colesevelam hydrochloride: A novel bile acid-binding resin
68. Reduction in incidence of coronary heart disease
69. Colesevelam hydrochloride (Cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects
70. A comparison of estrogen replacement, pravastatin, or combined therapy for the management of hypercholesterolemia in postmenopausal women
71. Effects of low dose simvastatin and hormone replacement therapy on serum lipids in postmenopausal women with hypercholesterolemia
72. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
73. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease
74. Treatment of hyperlipidemia with combined niacin-statin regimens
75. Lipid management: Tools for getting to the goal
76. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutarul-coenzyme A reductase
77. Does differing metabolism by cytochrome P450 have clinical importance?